
•Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect 
the integrity of the clinical study.Title: An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 with 
Cyclophosphamlde and Dexamethasone in.Patients with Newly Diagnosed Multiple Myeloma 
or Relapsed antVor Refractory Muµiple Myeloma Requiring Systemic Treatment 
Study ID: [REMOVED]
SAP Approve Date: 
22Aug 2016
Certain information  within this Statistical Analysis Plan has been r edacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information 
or company confidential information (CCI)
. 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
MLN9708 
Statistieal Analysis Plan Study C16020 
STATISTICAL ANALYSIS PLAN 
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 with 
C,clophosphamlde and Dexamethasone in.Patients with Newly Diagnosed Multiple 
Myeloma or Relapsed antVor Refractory Muµiple Myeloma Requiring Systemic 
Treatment 
SAP Version: 
Final 
Date 
Date 
Date 
Confidential Protocol#: C16020 Amendment 1 
Date of Statistical Analysis Plan: 
22Aug2016 
Approval Signatures 
1 
MLN9708
Statistical Analysis Plan Study C16020
2TABLE OF CONTENTS
LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS ......................................... 4
1.INTRODUCTION ............................................................................................................ 8
1.1Study  Design .............................................................................................................. 8
1.2Study  Objectives ........................................................................................................ 9
1.2.1 Primary Object ives.............................................................................................. 9
1.2.2 Secondary Object ives........................................................................................... 9
1.2.3 Exploratory  Object ives...................................................................................... 11
2.POPULATIONS FOR ANAL YSIS ................................................................................ 11
2.1Safet y Popul ation..................................................................................................... 11
2.2DLT -Evaluable Populat ion....................................................................................... 12
2.3Response- Evaluable Populat ion................................................................................ 12
2.4Pharmacokinet ic Analysis Populat ion....................................................................... 12
3.HYPOTHESES AND DECIS ION RULES ..................................................................... 12
4.INTERIM ANALYSIS ................................................................................................... 13
4.1Safet y Lead -in Evaluat ion........................................................................................ 13
4.2Continuous Monitoring and Early Stopping Rule ...................................................... 13
5.STATISTICAL METHODOL OGY ............................................................................... 14
5.1Sample Size Just ification .......................................................................................... 14
5.2Randomization and Stratificat ion.............................................................................. 15
5.3Unblinding ............................................................................................................... 15
5.4Data Handling .......................................................................................................... 15
5.4.1 Methods for Handling Missing Data ................................................................... 15
5.4.2 Definit ion of Baseline Values ............................................................................ 19
5.4.3 Windowing of Visits .......................................................................................... 19
5.4.4 Justificat ion of Pooling ...................................................................................... 19
5.4.5 Withdrawals, Dropouts, Lost to Follow-up ......................................................... 19
5.4.6 General Conventions for Determining Duration ................................................. 19
5.5Patient Disposit ion................................................................................................... 20
5.6Demographics and Baseline Character istics.............................................................. 20
5.6.1 Dem ographics .................................................................................................... 20
5.6.2 Disease Specific History .................................................................................... 20
5.6.3 Baseline Disease Characteristics ........................................................................ 21
5.6.4 Extent of Disease and Bone Marrow Cy togeneti c Resul ts at Baseline ................ 21
5.6.5 General Medical H istory .................................................................................... 22
5.7Treatments and Medicat ions..................................................................................... 22
5.7.1 Concomitant Medicat ions and Procedures .......................................................... 22
5.7.2 Study  Treatm ents............................................................................................... 22
5.8Efficacy Analyses ..................................................................................................... 24
5.8.1 Primary Efficacy Endpo ints............................................................................... 24
5.8.2 Secondary Efficacy Endpo ints........................................................................... 24
5.8.3 Exploratory  Efficacy Endpoints Analysis ........................................................... 25
5.9Analysis of Healt h Care Utilizat ion Data .................................................................. 28
5.10 Pharmacokinet ic, Pharmacodynamic ....................................................................... 28

MLN9708
Statistical Analysis Plan Study C16020
35.10.1 Pharmacokinet ic Analyses ............................................................................... 28
5.10.2 Pharmacodynamic Analyses ............................................................................. 30
5.11 Safet y Analyses ...................................................................................................... 30
5.11.1 Adverse Events ................................................................................................ 30
5.11.2 Laboratory  Data ............................................................................................... 34
5.11.3 Vital Signs ....................................................................................................... 35
5.11.4 Electrocardi ograms .......................................................................................... 35
5.11.5 Eastern Cooperative Onco logy Group Perform ance Status ............................... 36
5.11.6 Other Safet y Assessments ................................................................................ 36
6.CHANGES TO PLANNED A NALYSES FROM PROTOCOL ..................................... 36
7.PROGRAMMING CONSIDER ATIONS ....................................................................... 36
7.1Statist ical Software ................................................................................................... 36
7.2Rules and Definit ions............................................................................................... 36
8.REFERENCES ............................................................................................................... 36

MLN9708
Statistical Analysis Plan Study C16020
4LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation Term
5-HT 3 5-hydroxy tryptamine 3 serotonin receptor
AE adverse event
ALL acute ly mphoblastic leukemia
ALP alkaline phosphatase
ALT alanine aminotransferase
AML acute my elogenous leukemia
ANC absolute neutrophil count
API active pharmaceutical ingredient
aPTT activated partial thromboplastin time
Ara-C Cytarabine
ASCO American Society of Clinical Oncology
ASCT autologous stem cell transplant 
AST aspartate aminotransferase
AUC area under the plasma concentration versus time curve
BCRP breast cancer resistance protein
hCG beta-human chorionic gonadotropin
BID bis in die; twice a day
BM bone marrow
BSA body surface area
BUN blood urea nitrogen
BZD Benzodiazepines
CBC complete blood count
CFR Code of Federal Regulations
Cmax single -dose maximum (peak) concentration  
CNS central nervous system
CO 2 carbon dioxide
CR complete response    
CRM continual reassessment method
CRP C-reactive protein
CSF-1R colony-stimulating factor 1 receptor
CT computed tomography
CV coefficient of variation orcardiovascular choose one
CYP cytochrome P 450
DLT dose-limiting toxicity
DME drug metabolizing enzymes
DNA deoxyribonucleic acid
DOR duration of response   
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group

MLN9708
Statistical Analysis Plan Study C16020
5LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation Term
eCRF electronic case report form
EDC electronic data capture
ELISA enzyme-linked immunosorbent assay
EORTC QLQ -C30European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire 
EOS End of Study (visit)
EOT End of Treatment (visit)
EU European Union
FDA United States Food and Drug Administration
GCP Good Clinical Practice
G-CSF granulocyte colony stimulating factor
GGT gamma glutamyl transferase
GI Gastrointestinal
GLP Good Laboratory Practices
GM-CSF granulocyte macrophage -colon y stimulating factor
GMP Good Manufacturing Practice
Hb Hemoglobin
Hct Hematocrit
HDPE high-density polyethylene
HDT high-dose therapy
hERG human ether -à-go-go related gene
HIV human immunodeficiency virus
HNSTD highest no nseverely  toxic dose
IB Investigator’s Brochure
IC50 concentration producing 50% inhibition
ICF informed consent form
ICH International Conference on Harmonisation
IEC independent ethics committee
IMiD immunomodulating drugs
inc Including
IR Immunophenotype
IRB institutional review board
ITT intent -to-treat
IV intravenous; intravenously
IVRS interactive voice response system
Ki inhibition constant
KPS Karnofsky Performance Status
LDH lactate dehydrogenase
LFT liver function test(s)
Ixazomib Generic name of MLN9708

MLN9708
Statistical Analysis Plan Study C16020
6LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation Term
Millennium Millennium Pharmaceuticals, Inc., and its affiliates
MM multiple myeloma
MRD minimal residual disease
MRI magnetic resonance imaging
MRU medical resource utilization
MTD maximum tolerated dose
MUGA multiple gated acquisition (scan)
NCCN Natio nal Comprehensive Cancer Network
NCI Natio nal Cancer Institute
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NDMM newly  diagnosed multiple myeloma 
NPO nothing by mouth
nCR nearly  complete response
NYHA New York Heart Association
ORR overall response rate
OS overall survival 
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PD progressive disease (disease progression)
PFS progression -free survival 
Pgp P-glycoprotein
PK pharmacokinetic(s)
PN peripheral neuropathy
PO per os ; by mouth (orally)
POEMSpolyneuropathy , organomegaly, endocrinopathy, monoclonal gammopathy, and 
skin changes
PR partial response
PRO patient -reported outcome
PSA prostate -specific antigen
QD quaque die ; each day; once daily
QID quater in die; 4 times a day
QOD quaque altera die ; every other day
QOL quality  of life
QTc rate-corrected QT interval (millisec) of electrocardiograph
RBC red blood cell
RECIST Response Evaluation Criteria in Solid Tumors
RRAL relapsed and/or refractory systemic light chain amyloidosis
RRMM refracto ry multiple myeloma 
SAE serious adverse event
SC Subcutaneous

MLN9708
Statistical Analysis Plan Study C16020
7LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation Term
sCR stringent complete response
SCT stem cell transplant 
SD stable disease
SmPC Summary of Product Characteristics
t1/2 terminal disposition half -life
TGI tumor growth inhibition
Tmax first time of occurrence of maximum (peak) concentration
TTP time-to-progression 
UK United Kingdom
ULN upper limit of the normal range
US United States
VGPR very good partial response
VMP VELCADE to melphalan and prednisone 
WBC white blood cell
WHO World Health Organization

MLN9708
Statistical Analysis Plan Study C16020
81. INTRODUCTION
In general, the purpose of the statistical analysis plan (SAP) is to provide a framework that 
addresses the protocol object ives in a statist ically rigorous fashio n, wi thminimized bias or 
analyt ical deficiencies .  Specifically, this plan has the fo llowing purpose:
To prospectively (a priori) outline the ty pes of  analyses and data presentations that will 
address the study object ives outlined in the protocol, and to explain in detail how the data 
will be handled and analyzed, adhering to commo nly accepted standards and practices of 
biostatistical analysis in the pharmaceut ical industry.
1.1   Study Design
This is a n open -label , phase 2 study  designed to evaluate the safet y and efficacy  of the 
combinat ion ofIxazomib with cycl ophosphamide (C)and dexamethasone (d)in pat ients 
with NDMM who have not received prior sy stemic treatment for mult iple myelo ma (MM) 
and are ineligible for high -dose therapy  (HDT) -stem cell transplantati on (SCT) due to age or 
comorbid di sease(s), and in patients with RRMM who have received 1 to 3 lines of prior 
therapy  and whose disease is not refractory  to proteasom e inhibitors.
Patients wi th NDMM willreceive Ixazo mib in combinat ion with Cd f or an induct ion phase 
up to approximately 1 year (13 28-day cycles) and, if at least stable disease has been 
reached wit h an acceptable toxicit y profile after induction, patients will be administered, as 
maintenance, single -agent Ixazomib (at the dose tolerated at the end of induction) in 28- day 
treatm ent cycles until progressive disease ( PD), death or unacceptable toxicit y. 
Patients will 
be randomized 1:1 to either Arm A or Arm B,which have different doses of 
cyclophosphamide during induct ion peri od. During induction phase, each 28 -day treatm ent 
cycle consists of oral  Ixazo mib(4.0mg on Days 1, 8, and 15) administered in co mbinat ion 
with cycl ophosphamide (300 mg/m2[Arm A] OR 400 mg/m2[Arm  B] both on Day s1, 8, 
and 15) and dexamethasone (40 mg on Days 1, 8, 15, and 22) all administered orally .
Patients over 75 years of age will receive a reduced dose of dexamethasone 20 mg on the 
same weekly  schedule. During m aintenance phase, each 28 -day treatm ent cycle consists of
single agent oral Ixazomib(4.0 mg on Days 1, 8, and 15).
Patients wi th RRMM (Arm  C) will receive Ixazomib 4.0mg weekly on Days 1, 8, and 15, in 
combinat ion with cycl ophosphamide 300 mg/m2on Days 1, 8, and 15, and dexamethasone 
40mg on Days 1, 8, 15, and 22 of a 28 -day cycle (all orally administered).  Patients over 

MLN9708
Statistical Analysis Plan Study C16020
975years of age will receive a reduced dose of dexamethasone 20 mg on the same weekly 
schedule. Patients wi th RRMM will be enro lled to Arm C and treated until disease 
progression, death or unacceptable toxicit y.No m aintenance phase is planned for Arm C. 
For all t hree treatm ent arm s, asafet y lead-in evaluation will be performed after at least 
6patients in each treatment arm have had the opportunit y to com plete at least 1 cycle o f 
therapy .  DLTs observed in the first 6 patients in this treatment arm will be used to 
determine the safet y and overall tol erabilit y of the study  regimen and the feasibilit y of 
continued recruit ment of patients to the study .  
Patients will  attend an End-of-Treatm ent (EOT) visi t approxi mately 30 days after receiving 
their last dose of study  drug. Pati ents who stop treatment for any  reason other than PD will 
continue to have PFS fo llow-up visi ts. The PFS follow -up visit s shoul d occur every  8 weeks 
from EOT until the occurrence of PD or death, the patient withdraws consent for further 
follow-up, whichever comes first. 
The study  will be conducted to fully  characteri ze the safet y, tolerabili ty, efficacy, qualit y of 
life (QOL), and the pharmacokinetics (PK) of Ixazomib . 
1.2   Study Objectives
1.2.1   Primary Objectives
The primary  object ive for pati ents wi th newly diagnosed m ultiple myelo ma (NDMM) i s:
To determine the combined response rate of complete response (CR
)(including
stringent CR [sCR]) + very good parti al response (VGPR )following treatm ent of
oral Ixazo mib when added to a standard regimen of cyclophosphamide and low- dose
dexamethasone (Cd) during the induct ion phase.
The primary  object ive for pati ents wi th relapsed and/or refractory  multiple myel oma 
(RRMM) is:
To deter mine overall response rate (ORR; CR +VGPR +parti al response [PR]),
following treatm ent wi th oral Ixazo mib when added to a regimen of Cd.
1.2.2 Secondary Objectives
For pati ents wi th NDMM, t he secondary object ives are:

MLN9708
Statistical Analysis Plan Study C16020
10To evaluate the tolerabilit y and toxi city of the combinat ion of oral Ixazo mib with Cd
To characterize the PK in plasma of oral Ixazo mib in combinat ion with Cd
To determine overall response rate (ORR; CR +VGPR +PR), CR, VGPR, and PR
during the induction phase and the ORR (CR +VGPR +PR), CR +VGPR, CR,
VGPR, and PR throughout the entire treatment period
To determine time to response for patients who respond during the induct ion phase
To determine duration of response (DOR) for patients who respond during the
induct ion phase
To determine time to progression( TTP)
To evaluate PFS
To describe the safet y, tolerabilit y, and efficacy  of Ixazo mib as maintenance therapy
in patients who continue treatment beyo nd 13 cycles of induct ion therapy
To assess change in glo bal healt h status, as measured by  thepatient-reported
outcom e (PRO) instrument: European Organizat ion for Research and Treatment of
Cancer (EORTC) Qualit y of Life Quest ionnaire (QLQ -C30).
For pati ents wi th RRMM, the secondary  object ives are:
To evaluate the tolerabilit y and toxi city of the c ombinat ion of oral Ixazo mib with Cd
To characterize the PK in plasma of oral Ixazo mib in combinat ion with Cd
To determine CR +VGPR, CR, VGPR, and PR
To determine time to response for patients who respond
To determine DOR
To determine TTP
To evaluate PFS

MLN9708
Statistical Analysis Plan Study C16020
11To assess change in glo bal healt h status, as measured by  the pat ient-reported
outcom e (PRO) instrument: European Organizat ion for Research and Treatment of
Cancer (EORTC) Qualit y of Life Quest ionnaire (QLQ -C30).
1.2.3   Exploratory Objectives
The exploratory  objectives are:
2. POPULATIONS FOR ANAL YSIS
2.1   Safety Population
The s afety popul ation is defined as all pat ients who receive at least 1 dose of any study  drug.  
Patients will  be analyzed according to the treatment arm actually  received. The s afety 
popul ation will be used for safet y related analyses such as AE, concomitant m edicat ion, 
laboratory  tests, and vi tal signs. In addit ion, it will also be used for the analyses of TTP, PFS 
and QOL data.

MLN9708
Statistical Analysis Plan Study C16020
122.2       DLT -Evaluable Population
The DLT -Evaluable populat ion is defined as patients in the safet y lead-in cohort who 
receive all doses of Ixazomib and at least 80% of cyclophosphamide during Cycle 1 or 
experience a DLT in Cycle 1. Patients must take all doses in Cycle 1 as outlined in th e 
Schedule of Events if patients do not experience DLTs. The DLT -Evaluable populat ion will 
be us ed to eval uate the toxi cityand determine a tolerable do seand dose modificat ion 
following Cycle I of safet y lead-in.
2.3      Response -Evaluable Population
The response evaluable populat ion is defined as patients who receive at least 2 of the 3 
Ixazo mib doses during Cycle 1, have measureable disease at baseline, and at least 1 post -
baseline response as sessment. The response -evaluable population will be used for the 
analyses o f response r ates(RR) , time to response (TTR) , and duration of response ( DOR) . 
Measurable disease is defined by  the docum entati on of  at least 1 of the fo llowing 3 
measurements:
Serum  M-protein 1 g/dL ( 10 g/L).
Urine M -protein 200 m g/24 hours.
Serum  free light chain (FLC) assay:  involved free light chain level 10mg/dL
(100mg/L) provided the serum free light chain ratio is abnormal.
2.4     Pharmacokinetic Analysis Population
The Pharmacokinet ic analysis populat ion is defined as all patients who are enrolled in the 
safet y lead-in cohort and have sufficient dosing data and Ixazo mibconcentrati on-time data 
to permit calculat ion of Ixazo mibpharmacokinet ic parameters.
3. HYPOTHESES AND DECIS ION RULES
For patients with NDMM, the null hypothesis is that the combined CR+VGPR rate is not 
different in the treatment arms of Ixazo mib in combinat ion with cyclophosphamide and low -
dose dexamethasone fro m the specified response rate based on historical control, i.e.,
H0: CR+VGPR rate = 27%
The al ternat ive hypothesis is that Clinical response rate in the treatment arm is different 
from that of histori cal control , i.e.,

MLN9708
Statistical Analysis Plan Study C16020
13HA: CR+VGPR rate > 27%
For pati ents wi th RRMM , the null hypothesis is that the overall response rate (ORR: CR + 
VGPR + partial response [PR]) is not different in the treatment arm of Ixazo mib in 
combinat ion with cyclophosphamide and low -dose dexamethasone from the specified 
response rate based on historical control, i.e.,
H0: CR+VGPR +PR rate= 60%
The al ternat ive hypothesis is that Clinical response rate in the treatment arm is different 
from that of histori cal control , i.e.,
HA: CR+VGPR+PR rate > 60%
The one group chi
-square test will be used to test the hypothesis at a ty pe I error rate of 0.10 
(one -sided). 
4. INTERIM ANALYSIS
4.1   Safety Lead -in Evaluation
A safet y lead-in evaluat ion will be performed after at least6 safet y lead-in evaluable 
patients in each treatment arm have had the opportunit y to complete 1 cy cle of therapy . No 
formal statisti cal analysis is planned for the safet y lead-in evaluat ion.
4.2   Continuous Monitoring and Early Stopping Rule
There i s no form al interim analysis planned. Continuous data monitoring regarding safet y 
and efficacy  will be conducted based o n the Bay esian monitoring strategy . Two proportions 
will be calculated for each arm : PF, the proportion of patients who are considered an 
effect iveness success, and P S, the proportion of patients who experienced one or more 
Grade 4 or higher non -hematol ogical toxi cities. P Fwill be evaluated on the first 12 response -
evaluable patients and then every  6 addi tional response -evaluable patients ; PSwill be 
evaluated on the first 12 enrolled pat ients and then every 6 enro lled patients. 
If the stopping bounds of Ps≥4/12, Ps≥6/18, Ps≥7/24, and Ps≥8/30 for Arms A and B 
(patients wi th NDMM), or the stopping bounds of Ps≥4/12, Ps≥6/18, Ps≥7/24, Ps≥8/30, 
Ps≥9/36, Ps≥11/42, Ps≥12/48, Ps≥13/54, Ps≥14/60, Ps≥15/66, and Ps≥16/72 for Arm C 
(patients wi th RRMM) have been achieved, accrual to the study  will be suspended to allow 
for invest igation.  If the stopping rule is met, there is at least 80% probabilit y that the true 

MLN9708
Statistical Analysis Plan Study C16020
14toxicity rate will be greater than 18%.  After consideration by the study  team , a dec ision will 
be made as to whether accrual can be resumed.
If the futility stopping bounds (CR +VGPR) of PF2/12, PF4/18, PF7/24, and PF
10/30 for Arms A and B, or the futilit y stopping bounds (ORR) of PF≤5/12, PF≤12/24,
PF≤20/36, PF≤29/48 , and PF≤37/60 for Arm C have been met, further invest igation will
be made by the study  team  to assess if accrual to any  of the 3 treatm ent arm s may  be
terminated due to fut ility.  These fut ility stopping rul es are established to allow no larger
than 10% overall t ype I error rate (one -sided) and still maintain power of approximately
80%.
5. STATISTICAL METHODOL OGY
In general, summary tabulat ions will be presented todisplay the number of observati ons, 
mean, standard deviat ion, median, minimum, and maximum for continuous variables, and
the number and percent age(of non missing) per category  for categori cal data, unl ess 
specified otherwise . Patients will be analyzed at the dose l evel to whi ch they  were ori ginally 
assigned , unless specified otherwise , including those who receive subsequent treatment at a 
lower dose level or a higher dose level. Tables will be summarized by  treatm entarms .
At the time of clinical study  report( CSR )lock, all relevant data will be queried and cleaned; 
a database snapshot wi ll be taken and used for the CSR. Addit ional treatm ent data will be 
entered into the database through study  terminat ion. Analyses may  be updated based on 
additional information. An addendum to the CSR may be written if warranted based on these 
analyses .
5.1  Sample Size Justification
This is a 3-arm open -label , mul ticenter, phase 2 study  designed to evaluate the efficacy  and 
safet y of the oral com binat ion ofIxazo mib withcyclophophamide and dexamethasone in 
patients wi th NDMM (Arm  A or Arm  B) or patients wi th RRMM (Arm C) . 
For pati ents wi th NDMM (A
rm A or Arm  B), the sample size is calculated by using one
group chi-square test for each arm separately based on the CR + VGPR rate following 
Ixazo mib combined treatment regimen. Wit h 31 response -evaluable patients per treatment 
arm(Arm  A or Arm  B), there will be 80% power to test a null hypothesis CR + VGPR rate 
of 27% and an alternative hypothesis CR +VGPR rate of 45% at 1- sided significant level o f 
α =0.10.  Assuming 10% patients are not response evalu able, approximately  35patients 
each (70 total) will  be enrolled in these 2 treatm ent arms (Arm  A and Arm  B).

MLN9708
Statistical Analysis Plan Study C16020
15For pati ents wi th RRMM (Arm C), the sample size is calculated by  using onegroup 
chi-square test based on the ORR rate following a Ixazo mib combin ed treatm ent regimen.  
With 71 response -evaluable pat ients in Arm C, there will be 80% power to test a null 
hypothesis ORR rate of 60% and an alternative hypothesis ORR rate of 72% at 1 -sided 
significant level of α =0.10.  Assuming 10% patients are not re sponse evaluable, 
approximately  78patients will be enrolled in Arm C.
Overall, approximately  148 pati ents will be enrolled in this study . 
5.2   Randomization and Stratification 
For pati ents wi th NDMM (Arm  A or Arm  B), a central  (not center specific) rando mizat ion 
scheme will be used . Eligible pat ients will be randomized to Arm A or Arm B at a rati o of 
1:1.  Arando mizat ion number will be assigned to each patient.  The rando mizat ion 
assignment will be implemented by an interactive web response system (IWRS).  
Randomization is not required if accrual to either Arm A or Arm B is stopped, and therefore 
the enrollment can remain open for the other arm . 
For pati ents wi th RRMM (Arm C), randomizat ion will not be used but an IW RS will be 
implemented for enrol lment .  
5.3   Unblinding
This is an open -label study .  No unblinding methodology  is requi red.
5.4   Data Handling
5.4.1    Methods for Handling Missing Data
All available efficacy and safet ydata will be included in data list ings and tabulations.  Data 
that are potentially spurious or erroneous will be examined under the auspices of standard 
data m anagement operati ng procedures. Noimputation of missing data will be performed 
unless specified.  
5.4.1.1      Missing Data in Patient Reported Outcomes (PROs)
For PRO data , missing data imputation will be based on published instrument specific 
methods .
For QOL in EORTC QLQ -C30, if a mult i-item subscale has a missing item, then the average 
of the remaining items will be used as the Scale score, as long as at least half the it ems in 

MLN9708
Statistical Analysis Plan Study C16020
16that Scal e are present.  Example:  for fat igue, if Item 12 is missing, the average score of 
Items 10 and 18 will be used.
5.4.1.2    Missing/Partial Dates in Screening Visit
The fo llowing rul es apply to dates recorded during the screening visit s. 
1.If only  the day -component is missing, the first day of the month will be used if the 
year and the month are the same as those for the first dose of study  drug .  Otherwi se, 
the 15th will be used. 
2.If only  the year is present, and it is the same as the year of the f irst dose of study  
drug, the 15th of January  will be used unless it is later than the first dose, in which 
case the date of the firstof January  will be used. 
3.If only  ayear is present, and it is not the same as the year of the first dose of study  
drug, the 15th of June will be used, unless other data indicate that the date is earlier.  
5.4.1.3    Missing/Partial Dates in Adverse Events/Concomitant Therapies/Subsequent 
Therapies
5.4.1.3.1    Missing/Partial Dates in Adverse Events
Adverse events with stop dates that are completely or partially missing will be imputed as 
follows:
1If the stop date has month and y ear but day  is missing, the last day  of the m onth will 
be imputed
2If the stop date has y ear, but day  and m onth are missing,  the 31th of December will 
be imputed
After the imputati on, the imputed dates will be compared against the date of death, if 
available.  If the imputed date is later than the date of death, the date of death will be used as 
the imputed date instead. If the stop date of an adverse event is co mpletely missing, then this 
event will be regarded as ongoing and will be included in the summary table.
Adverse events with start dates that are completely or partially missing will be imputed as 
follows:
1.If the start date has month and year but day  is missing

MLN9708
Statistical Analysis Plan Study C16020
17a.Ifthe onset m onth and year are same as that of first dose date, the f irst dose 
date will be used instead . If the onset m onth and year are different from that 
of the first dose date, then the first day  of the month will be used.
b.After imputation, the imputed dates will be co mpared against the stop date. If 
this imputed date i s later than the stop date (possibly  imputed), then the stop 
date will be used instead
2.If the start date has y ear, but day  and m onth ar emissing
a.If the onset year i s same as that of first dose date, then the first dose date will 
be used instead
b.If onset y ear is different than that of the first dose date, the 1stof January  of 
the year will be imputed.
c.After the imputation, the imputed dates will be compared against the dose 
stop date. If this imputed date i s later than the stop date (possibly imputed), 
then the stop date will be used instead.
If the start date of an adverse event is completely missing, then it is imputed wi th the first 
dose date.
5.4.1.3.2    Missing/Partial Dates in Concomitant Therapies
Concomitant therapies wit h start dates that are completely or partially missing will be 
analyzed as fo llows:
1.If the start date has month and year but day  is mis sing, the therapy  will be included in 
the summary  table if the m onth and year are: 
a.On or afterthe month and y ear of  the date of the first dose of study  drug
and 
b.On or before the month and year of the date of the last dose of study  drug 
plus 30 days.
2.If the start date has y ear, but day  and m onth are missing, the therapy  will be included 
in the summary table if the year is:

MLN9708
Statistical Analysis Plan Study C16020
18a.On or after the year of the date of the first dose of study drug
and
b.On or before the year of the date of the last dose of study  drug plus 30 day s.
If the start date of concomitant therapies is completely missing and the stop date of 
concomitant therapies is prior to the date of the first dose of study  drug, then this therapy  
will not be included . 
If the start date of concomitant therapi es is com pletely  missing and the stop date of 
concomitant therapies is on or after the date of the first dose of study  drug, then the therapy  
will be included in the summary  table.
If the start date and stop date of concomitant therapies are complet ely missing, then the 
therapy  will be included in the summary table.
5.4.1.3.3    Missing/Partial Dates in Subsequent Therapies
Subsequent therapies wit h start dates that are completely or partially missing will be 
analyzed as fo llows:
1.When monthand y ear are present and the day  is missing,
a.If the onset month and year are the same as the month and y ear of last dose of
study  drug, the day  of last dose + 1 will be imputed.
b.If the onset month and year are not the same as the month and year of l ast dose of
study  drug, the fi rstday of the month is imputed.
2.When only  a year is present,
a.If the onset year is the same as the y ear of  last dose ofstudy  drug, the date of l ast
dose + 1 will be imputed.
b.If the onset year is not the same as the y ear o f last dose ofstudy  drug, the first
day of the year i s imputed.
      If no components of the onset date are present the date of last dose + 1 will be imputed.

MLN9708
Statistical Analysis Plan Study C16020
195.4.2    Definition of Baseline Values
In general, the baseline value is defined as the value coll ected at the time closest to, but 
prior to, the first dose of study  drug on Day  1 of Cycle 1.  For example, this applies to most 
of safet y chemistry  and hematol ogy labs.
However, for certain efficacy related labs (serum and urine M -protein, free light chai n, 
response bio markers etc) ,baseline is defined as the worst value (usually highest but could be 
lowest in som e cases for certain bio markers) fro m central  labs (both scheduled and 
unscheduled) prior to first dosing. Ifall central  labs are missing, then t he worst value 
obtained from local lab (both scheduled andunschedul ed)will be used.  Pl ease note that 
decisio ns regarding eligibilit y (such as response evaluable) may be made using either local
or central laboratory .
5.4.3    Windowing of Visits
All data will be categorized based on the scheduled visit at which they were collected .  
These visit designators are pre defined values that appear as part of the visit tab in the eCRF .  
5.4.4    Justification of Pooling
All data from all sites will be pooled . Study  center or treatment -by
-center interaction will 
not be included in any statistical analysis.
5.4.5    Withdrawals, Dropouts, Los tto Follow -up
Time to event parameters will be censored if pat ients withdraw, drop out, or are lost to 
follow-up before docume ntation of  the events (progressive disease /death).  Rules for 
censoring are detailed in sect ion 5.8.2.
5.4.6    General Conventions for Determining Duration
The durati on of  an event i s calculated as: date of end of the e vent –date of start of the event 
+1. It shall be used for deriving the duration form a reference time point, e.g., days on 
treatm ent = date of l ast dose -date –date of first dose +1 and for time to event analyses such 
as survival or time to tumor progression. Table, listing, figure ( TLF)shell s will specify if 
there are exceptions.

MLN9708
Statistical Analysis Plan Study C16020
205.5   Patient Disposition
The disposi tion of  patients includes the number and percentage of pat ients for the following 
categori es:patients in each of the study popul ation,patients discontinued fro m the treatm ent 
regimen , primary reason for discont inuat ion from the treatment regimen , pati ents ongoing in 
follow
-up, patients off study  during fo llow-up and primary  reason off study  during fo llow-
up. Percentages will be presented for each arm and the total of Arm A + Ar m B.Patient 
disposi tion will  be summarized and listed. The number and percentage of patients 
discontinued fro m the treatm ent regimen, primary  reason for di scont inuat ion from the 
treatm ent regimen will also be summarized for induction phase and maintenance phase 
separately  for Arm  A, Arm  B and the total  of Arm A + Arm  B.
5.6   Demographics and Baseline Characteristics
5.6.1    Demographics
Dem ographic data will be summarized by each treatm ent armand by the total of Arm A + 
Arm B.  Baseline demographic data to be evaluated include gender, age, race, ethnicit y, 
height, weight ,body surface area (BSA) , and other parameters as appropriate . 
No inferent ial 
statist ics will be carried out.
Age will be calculated fro m date of birth and date of informed consent. 
The formulat ion for BSA (Mosteller , 1987 ) is:
BSA = sqrt(h eight(cm ) x weight (kg) / 3600).
5.6.2    Disease Specific History
Disease specific history  will be summarized to include type of myelo ma at diagnosis, Durie -
Salmo n stage at diagnosis, International Stage System (ISS) at diagnosis, evidence of lyt ic 
bone disease and extramedullary disease, and the prior therapies for patients with RRMM 
(number of patients with prior therapy , lines o f prior therapi es,  best hem atological response 
to pri or therapy , type of pri or therapy  in the form at of therapy  contained, number of pat ients 
who received VELCADE as the last line of prior therapy, number of patients refractory to 
any line o f prior therap y). Disease specific history will be summarized and listed by each 
treatm ent arm  and by the total of Arm A + Arm B. The m onths from prior diagnosis to the 
first dose of ixazomib is calculated by  

MLN9708
Statistical Analysis Plan Study C16020
21first	dose	date	 -	date	of	diagnosis	
365.25/12
5.6.3    Baseline Disease Characteristics
Baseline disease characteri sticswill be summarized by  each treatm ent armand the total  of 
Arm A + Arm  B including serum  M-protein, urine M -protein, serum  free light chain, serum  
free light chain rat io,2-microglobin and its category ( i.e., < 2.5, 2.5 -5.5, > 5.5 mg/L), 
serum  creat inine and its category, (<=2, >2 mg/dL), calculated creatinin e clearance and its 
category  (<30, 30 -<60, 60- <90, >= 90 m L/min), serum  albumin by category  (i.e., <3.5,
>=3.5 g/d L), corrected calcium, hemoglo bin, platelet count, neutrophil count, LDH and 
Eastern Cooperative Oncology  Group (ECOG) performance status. 
Creatinine clearance will be calculated using the Cockcroft -Gault formulas as fo llows:
For m ale pat ients: 
For fem ale patients:
Integer values will be used. 
For pati ents wi th heavy  chain, the patient’s t ype of myelo ma is determined by the 
combinat ion of heavy chain t ype (IgG, IgA, IgM, IgD, and other) and light chain t ype 
(Kappa, Lambda, and biclo nal). In descript ive summaries, the disease will be categorized by 
the heavy chain t ype first, then wit hin each of these categories, patients will be further 
classified according to their light chain t ype. For pati ents wi th light chain only, patients will 
be classified acco rding to their light chain t ype.
5.6.4    Extent of Disease and Bone Marrow Cytogenetic Results at Baseline 
The extent of disease at baseline will be summarized including number of patients with a 
bone marrow aspirate, bone marrow aspirate results (% plasma c ells, % megakary ocytes [mg/dL]) creati nine (serum72weight[kg] Age[yrs]) (140clearance creati nine 
[mg/dL]) creati nine (serum72weight[kg] Age[yrs]) (14085. 0 clearance creati nine  

MLN9708
Statistical Analysis Plan Study C16020
22present), number of patients with a bone m arrow bi opsy, bone m arrow bi opsy  resul ts (% 
plasma cells, % cellularit y, type of  cellularit y, % Kappa/Lambda ratio performed), skeletal 
survey results (normal, abnormal not clinically signifi cant, abnormal  clinically significant, 
and not done) and imaging including magnet ic resonance imaging ( MRI ) / com puted 
tomography  (CT) resul ts (norm al, abnorm al not clinically significant, abnormal clinically  
significant, and not done), number and percenta ge of ly tic bone l esionspresent ,  number of 
extram edullary  plasmacy tomapresent , and ty pe of  extram edullary  plasmacy toma. 
Bone m arrow cy togeneti c resul ts at baseline from  the convent ional/kary otype and 
molecular/FISH cy togeneti c analyses m ethods will be displayed. The results will be 
categori zed as “Norm al”, “Abnorm al” and “Indeterminate”. The percentage of each 
category  will be summarized.   Abnormal types of interest, including but not limited to ,del 
13, del  17, t(4;14), t(11;14), t(14;16) , -13q, -17p, hyperdiplo idy,hypodi ploidyand high risk 
cytogeneti cs group (del 17, -17p, t(4,14) or t(14,16) ), will also be tabulated. 
By-patient listings for these baseline characterist ics will also be presented.
5.6.5    General Medical History 
General medical history  data will be presented in a by -patient listing. 
5.7   Treatments and Medications
5.7.1    Concomitant Medications and Procedures
Concomitant medicat ions will be coded by generic term using the Worl d Heal th 
Organizat ion (WHO) Drug Dict ionary.  The number and perc entage of patients taking 
concomitant medicat ions will be tabulated by  WHO drug generic term from the first dose of 
study  treatm ent through 30 day s after the l ast dose of study  medicat ion. Concomitan t 
procedures will not be coded.
Concomitant medicat ions and procedures will be presented in by- patient listings.
5.7.2    Study Treatments
Eligible pat ients will take Ixazo mib in combination with Cd. Patients with NDMM will be 
rando mized to either to Arm A or Arm B . Pati ents wi th RRMM will be enrolled in Arm C.
During induct ion, patients wi th NDMM will be randomized to receive a combinati on of  oral 
Ixazo mib at a dose of 4.0 m g and a dose of cy clophosphamide at 300 m g/m2(Arm  A) or 400 

MLN9708
Statistical Analysis Plan Study C16020
23mg/m2(Arm  B) on day s 1, 8 and 15 of a 28- day cycl e and dose of 40 mg of dexametha sone 
on Day s 1, 8, 15, and 22 of a 28- day cycle; pat ients with RRMM will receive a combinat ion 
of oral Ixazo mib at a dose of 4.0 mg and a dose of cy clophosphamide at 300 m g/m2on day s 
1, 8 and 15 of a 28- day cycle and a dose of 40 mg of dexamethasone on Da ys 1, 8, 15, and 
22 of a 28- day cycle. Patients over 75 y ears of age will receive a reduced dose of 
dexamethasone 20 mg on the same weekly schedule. 
At the end of the induction phase, a maintenance phase starts for patients with NDMM
(Arms A and B only) who have at least stable disease. Patients will receive single -agent 
Ixazo mib(at the dose tolerated at the end of inductio n phase )on Days 1, 8, 15 of 28 -day 
cycles unt il progression/death or unacceptable toxicit y.  
5.7.2.1    Extent of Exposure
A pat ient will be considered astreated in a cy cle as l ong as this patient received any  amount 
of study  drug in that cycle . A treatm ent cycle is defined as a cy cle in which the pat ient 
received any amount of study  drug. A treatm ent cycle for a specific drug is defined as a 
cycle in which the pat ient received any amount of that drug.
Relative dose intensit y (%) is defined as 100 × (total amount of dose taken (mg)) / (sum of 
the planned dose over all treatm ent cycles).
The exposure to each study  drug will be summarize d inc luding the number of cy cles, total  
amount of dose taken (in mg ), total  number of do ses taken, number and percentages of 
patients by treatm ent cycles, and relative dose intensit y. An aggregate summary  of numbers 
and percentages of pat ients who had 1- 6, 7-13, 14-20, 21 -26, >26 treatm ent cy cles will also 
be presented in the same table. 
Exposure of Ixazo mibwill be presented by overall treatm ent peri od, inducti on period (Arms 
A and B only), and maintenance period (Arm s A and B only) . The summary of each study  
drug exposure will be presented by  each treatment arm and the total of (Arm A + Arm B) in 
a similar format. 
Dosing data will also be presented in a by- patient list ing.
5.7.2.2    Treatment Modifications
The actions for each study  drug (dose reduction, held, mis sed, increase d,delayed , 
discontinued permanent ly,etc) will be summarized for all pat ients, over all treatment 

MLN9708
Statistical Analysis Plan Study C16020
24periods, and by  each cycle for Cycle 1 though Cycle 13, aggregated for Cycles 1 -6, 7-13 
(for all drugs) and then for the remainder of cy cles.
5.8   Efficacy Analyses
Response will be assessed according to the International Myelo ma Working Group (IMWG) 
criteria for all pat ients at every cycle during the treatment period and subsequently every 8 
weeks during the PFS follow -up peri od unt il disease progression or the pati ent is off the 
study . Other efficacy  parameters including ,but not limited to time to , time to response 
(TTR) and durati on of  response (DOR) will be presented in list ings and summarized if 
appropriate . Summary of best M -Protein Response to t reatm ent will also be presented.
Subgroup analysis by age, ISS stage, creatinine clearance, ASCT, lines of prior therapy  
(RRMM), e tc may also be expl ored f or som e efficacy  endpoints.
5.8.1    Primary Efficacy Endpoints
For pati ents wi th NDMM, t he primary  endpoint is the combined response rate of CR + 
VGPR during the induction phase .For pati ents wi th RRMM, the primary  endpoint i s ORR. 
Theprimary  efficacy  analysis will bebased on the response -evaluable population. Estimates 
of CR + VGPR and ORR will be calculated wi th 2-sided 95% exact bino mial confidence 
intervals.
5.8.2    Secondary Efficacy Endpoints
For pati ents wi th NDMM, s econdary effica cy endpoints include ORR (CR + VGPR + PR ), 
CR, VGPR, PR rate during the induct ion phase, and ORR (CR + VGPR + PR), combined 
response rate (CR + VGPR), VGPR, CR,PRthroughout the entire treatm ent peri od; TTR,
DOR for pati ents who respond during the induct ion phase, TTP, PFS throughout the ent ire 
treatm ent peri od.  
For pati ents wi th RRMM, secondary efficacy endpoints include combined response rate (CR 
+ VGPR), VGPR, CR, PR , TTR , DOR, TTP, PFS.
Time to response (TTR) is defined as the ti me from the date of  first dose of study  treatm ent 
to the date of the first documentation of a confirmed PR or better response up to the 
initiation of alternat ive therapy in a pati ent who responded.
DOR i s defined as the time from the date of first document ation of  a confirmed PR or better 
to the date of first docum ented PD up to the initiation of alternative therapy . Responders 

MLN9708
Statistical Analysis Plan Study C16020
25without documentation of PD will be censored at the date of the last response assessment
that is SD or better prior to the date of the initiation of alternative therapy . DOR will  be 
categori zed as CR+VGPR+PR, CR+VGPR, and CR.
TTP is defined as the time fro m the date of first dose of study  treatm ent to the date of first 
docum entati on of  PD. Pati ents wi thout docum entati on of PD will  be censored at the date of 
the last response assessment that is SD or better prior to the date of initiation of  alternative 
therapy . Pati ents wi th no response assessment will be censored at the date of first dose.
PFS i s defined as the time from the date of first dose of study  treatm ent to the date of first 
docum ented PD or death. Pati ents wi thout docum entati on of  PDor death will be censored at 
the date of the last response assessment that is SD or better prior to the date of initiation o f 
alternat ive therap y.Patients wi th no response assessment will be censored at the date of first 
dose.
Time -to-event data will be summarized by 25th, 50th(median), and 75thpercent iles wit h 
associ ated 2 -sided 95% confidence intervals, as well as percent of censored observat ions.
The response rates, time to response, and DOR will be analyzed based on Response -
Evaluable populat ions. TTP andPFS will be analyzed based on the safet y popul ation. The 
response rates will be analyzed similarly to the pr imary endpo int. DOR, TTP and P FSwill 
be analyzed using standard survival analysis techniques based on Kaplan -Meier estimates.
The efficacy results will be summarized for each treatment arm and for the total of Arm A 
and Arm B.
5.8.3      Exploratory Efficacy Endpoints Analysis
5.8.3.1    Minimal Residual Disease Analysis 

MLN9708
Statistical Analysis Plan Study C16020
265.8.3.2    Patient Reported Outcome Analysis (PRO)
Qualit y of Life will be assessed using the EORTC QLQ -C30 and analyses will be perform ed 
using the safet y popul ation for each treatment arm and the total of Arm A +ArmB.
Descript ive statistics will be presented for the change fro m baseline in QOL assessment over 
time. For pati ents wi th NDMM who enter m aintenance therapy  after 13 cy cles of inducti on 
treatm ent, descri ptive statist ics will be presented for the change fro m baseline and change 
from Cycle 13 in QOL assessment over time. Analyses will be performed on summary 
scores as well as subscale scores .
The scale/subscale scores of EORTC QLQ -C30 are defined as shown in Table 5 -1.Primary 
subscales for analysis (with associated items in parenthesis) include Pain (items 9, 19), 
Fatigue (items 10, 12, 18), Physical funct ioning (i tems 1 -5), and Global healt h status/QOL 
(items 29- 30).  Secondary  subscales for analysis include Nausea/Vo miting (items 14- 15), 
Dyspnea (item 8), Insomnia (item 11), Appetite loss (item 13), Constipat ion (item 16), 
Diarrhea (i tem 17), Financial difficult ies (item 28), Role funct ioning (i tems 6
-7), Cogni tive 
funct ioning (items 20, 25), Emotional functioning (it ems 21- 24), and Social functioning 
(items 26- 27).  QOL data will be reported for the responders ( confirmed best response of 
CR+VGPR+PR ) and non -responders to assess the QOL differences associated with disease 
response. In addit ion, PRO responder analyses b y tum or responder groups will be 
perform ed, where PRO responders are defined as patients who improved by  10points or 
more on the EORTC QLQ -C30 global health scale at any t ime post -baseline, and tumor 
responders are defined as CR+VGPR+PR, CR+VGPR, and CR r espect ively.
Published scoring manual and guidelines will be used to determine EORTC QLQ -C30 scale 
scores and handle missing data.  Further invest igatio n of missing patterns, imputation and 
subsequent sensit ivity analyses may  be conducted.

MLN9708
Statistical Analysis Plan Study C16020
27Table 5 -1   Definition of Subscale Scores of EORTC QLQ -C30
Scale/Subscale Individual Items
Physical functio ning 1-5
Role functioning 6-7
Emotio nal functioning 21-24
Cognitive functioning 20, 25
Social functioning 26-27
Quality  of life 29-30
Fatigue 10, 12, 18
Nausea and vomiting 14-15
Pain 9, 19
Dyspnea 8
Insomnia 11
Appetite loss 13
Constipation 16
Diarrhea 17
Financial difficulties 28
5.8.3.3    Efficacy Assessment as Maintenance Therapy 
For patients with NDMM who enter m aintenance therapy after 1 3cycles of induction 
treatm ent, the efficacy of Ixazomib as maintenance therapy  will be evaluated.  The durati on 
of maintenance therapy  will be further explored.  Addit ional efficacy endpo ints include shift 
table for response categori es, landmark analysis of PFS, and other efficacy  endpoints if 
appropriate in the maintenance therapy porti on of  the study . For the efficacy endpo ints 
above, the staring time po int will be the first date of maintenance therapy.
5.8.3.4 Biomarker Analysis 

MLN9708
Statistical Analysis Plan Study C16020
285.9   Analysis of Health Care Utilization Data
Analyses of healt h care utilizat ion data will be performed using the safet y populati on and 
summarized for each treatment arm and by the total o f Arm A + Arm B. In general , 
descript ive statistics of medical encounters (length of stay, inpat ient, outpati ent, and reason), 
and number of missing days from work or other activit ies by pat ient and caregiver will be 
presented .  
5.10   Pharmacokinetic , Pharmacodynamic
5.10.1    Pharmacokineti c Analyses
The PK analysis populat ion will be used for the descript ion of the PK profile and for the 
calculat ion of PK parameters.
Safety Lead -in Cohort
PK evaluat ion will be based on concentrations o f Ixazo mib in specimens collected at pre -
specified t imes prior to and following drug administration. Actual specimen co llection times 
will be used for the calculat ion of PK parameters. In the event that actual collect ion times 
are ei ther unreliable or missing, scheduled collection times will be used. For ease o f 
presentation, scheduled co llection times will be used to present results in tables and figures.  
Both scheduled and actual co llection times will be presented in list ings.
Concentrations of Ixazo mibthat are bel ow the limit of quantificat ion (BLQ) will be treated 
as zero. Concentration data that are considered anomalous may be excluded from the 
concentration summaries and plots and will not be used in the calculation o f PK parameters. 
Evidence or expl anations will be provided to justify the exclusio n of da ta.
When summarizing concentrations or PK parameters, a minimum of 2 values are required to 
show the m ean and geometric mean, and at least 3 values are required to show the standard 
deviat ion and coefficient of variat ion (CV). 
Individual pat ient plasma co ncentrati on data will be listed.  Concentrations will be 
summarized (N, mean, standard deviat ion, CV, geometric mean, median, minimum, and 
maximum) according to Arm (A, B, or C) and dosing cycle and day .  
A semi -logarithmic pl ot of  the mean plasma concent ration-time curves of 
ixazo mibfollowing Cycle 1, Day  1 dosing (pre -dose to 168 hours) and Cy cle 1, Day  15 
dosing (pre -dose to 336 hours) will be provided, respect ively. Linear and semi -logarithmic 

MLN9708
Statistical Analysis Plan Study C16020
29plots of  the aggregate individual plasma concentratio n-time curves (“spaghetti” plots) of 
ixazo mibfollowing Cycle 1, Day  1 dosing (pre -dose to 168 hours) and Cy cle 1, Day  15 
dosing (pre -dose to 336 hours), grouped according to Arm will be provided, respectively. In 
linear plots, a value o f zero will be subst ituted for any BLQ values. In semi -logarithmic 
plots, BLQ values will be treated as missing.
Pharmacokinet ic parameters will be calculated using non -compart mental analysis methods.  
The fo llowing PK parameters will be computed, as data permits, from concentrati on-time 
data: 
Parameter Definition Units
Cmax Observed maximum concentration ng/mL
Tmax First time C maxis observed hr
AUC tau Area under the concentration -time curve from time 0 to the end of the 
dosing interval, estimated using the linear -log  trapezoidal methodhr*ng/mL
λz Terminal disposition phase rate constant 1/hr
t1/2 Terminal disposition phase half -life hr
Rac Accumulation ratio unitless
Different PK parameters will be calculated following dosing on Day  1and Day  15. 
The PK parameters to be estimated for each day  of dosing are as follows:
PK ParameterDosing Day
1 15
Cmax X X
Tmax X X
AUC tau  (tau = 168 hr) X X
λz X
t1/2 X
Rac X
Individual pat ient parameter data will be listed. PK parameters will be summarized (N, 
arithmetic m ean, standard deviat ion, CV, geom etric m ean, m edian, minimum, and 
maximum) according to Arm and dosing cycle and day .

MLN9708
Statistical Analysis Plan Study C16020
30All Patients
Concentration -time data from pat ients not in the safet y lead-in cohort will be listed only. 
Pharmacokinet ic data collected for all patients including patients in the safet y lead-in cohort 
of the study  maybe used to perform populat ion PK analysis using a nonlinear mixed ef fects 
modeling approach to assess the effect of various demographic covaria tes on PK including 
data from  other studi es of  Ixazo mib, if possible.
5.10.2    Pharmacodynamic Analyses 
Not applicable
5.11   Safety Analyses
Safety analysis will be performed using the safet y popul ation by each treatment arm or the 
total of Arm A + Arm  B. Summar y tabulat ions will be presented to display thefrequency  of
incidence, intensit y, type of AEs, ECGs, vital sign measurements, and clinical laboratory  
resul ts.  
For the lead in pat ients, the incidence of DLT will be listed. 
5.11.1    Adverse Events
5.11.1.1    Adverse Events
Adverse events will be coded using the Medical Dicti onary  for Regulatory  Activities 
(MedDRA ).AEs will be reported from the first dose of study  drug through 30 day s after 
administration of the last dose of study  drug. All AEs will be presented in a by-patient 
listing.AEs will be tabulated according to the MedDRA by system organ class, high level 
terms and preferred terms. T reatment -emergent is defined as any  AE that occurs after 
administration of the first dose of any study  treatment through 30 days after the l ast dose of 
any study  treatm ent.
Summary  tabulat ions will include the following categori es:
Treatment -emergent AEs
Drug -related treatment -emergent AEs

MLN9708
Statistical Analysis Plan Study C16020
31Grade 3 or higher treatment -emergent AEs (also grade 3 only and 4 only will be
reported seperately)
Grade 3 or higher drug- related treatment -emergent AEs (also grade 3 only and 4 only
will be reported separately )
The m ost comm only reported treatm ent-emergent AEs (i.e., those events reported by
> 10% of all patients)
Serious adverse events
Treatm ent-emergent AEs result ing in study  drug reducti on
Treatment -emergent AEs result ing in any study  drug discont inuat ion
For pati ents wi th NDMM who enter m aintenance therapy after 13 cy cles of inducti on 
treatm ent, AEs will be tabulated according to the MedDRA by system  organ cl ass, high 
level terms and preferred terms for induct ion phase and maintenance phase. Summary 
tabul ations will include the fo llowing categori es: 
Treatment -emergent AEs
Grade 3 or higher treatment -emergent AEs
Serious adverse events
Treatment -emergent AEs result ing in study  drug reducti on
Treatment -emergent AEs result ing in any study  drug discont inuat ion
Patients wi th the sam e AE m ore than once will have that event counted only  once wi thin 
each body  system, once wi thin each hi gh level ter m, and once wi thin each preferred term.  
Drug -related treatment -emergent AEs will also be summarized by the Nat ional Cancer 
Institute Common Toxic ity Criteria (NCI CTC AE) versio n 4.03AE(1). Patients wi th the 
same AE more than once will have the maxim um intensi ty of that event counted once within 
each body  system, once wi thin each hi gh level term, and once within each preferred term . 

MLN9708
Statistical Analysis Plan Study C16020
32Most commo nly reported (at least 10% of all pat ients) treatment -emergent AEs will be 
presented by preferred term only. Patients wi th the sam e AE m ore than once will have that 
event counted only once wit hin each preferred term.
An overall summary AE table will include numbers and percentages of patients who had any 
AE, drug -related AE, grade 3 or higher AE, grade 3 or high er drug -related AE, serious AE 
(SAE), drug- related SAE, AE result ing in any drug discont inuat ion, AE result ing inany
dose reduction, AE result ing in any dose m odificatio n (defined as delay, reduct ion or 
discontinuat ion), and on -study  deaths. On -study  deat h is defined as the death that occurs 
between the first dose of study  drug and up to 30 days after the last dose .
Addit ionally , by-patient list ings of the AE of special interest will be presented including 
rash, peripheral neuropathies, thrombocy topenia, and gastrointestinal disorders ,if 
appropriate.
5.11.1.2    Peripheral Neuropathy Events

MLN9708
Statistical Analysis Plan Study C16020
335.11.1.3    Serious Adverse Events
The number and percentage of patients experiencing at least one treatment -emergent SAE 
will be summarized by  MedDRA prima ry system  organ class, hi gh level term , and preferred 
term. Drug -related SAE swill be summarized similarly .
In addit ion, a by -patient listing of the SAEs will be presented (the list ing will contain all 
SAEs regardless of treatment -emergent AE status).
5.11.1.4    Deaths
A by-patient listing of the on-study  deaths will be presented.  On -study  death is defined as 
the death that occurs between the first dose of study drug up to 30 days after the last dose of 
study  drug.
5.11.1.5    Adverse Events Resulting in Discontinuation of Study Drug
The number and percentage of patients experiencing at least one adverse event result ing in 
discontinuat ion of any study  drug will be summarized by  MedDRA system  organ cl ass, high 
level term, and preferred term.
A by-patient listing of treatm ent-emergent AEs result ing indiscont inuat ion of any  study  
drug will be presented.  All AEs resul ting in discont inuat ion of any  study  drug occurring on -
study  will be displayed.
5.11.1.6    Adverse Events Resulting in Dose Reduction
The number and percentage of patients experiencing at least one adverse event result ing in 
any dose reducti on will be summarized by  MedDRA system  organ class, high level term, 
and preferred term.
A by-patient listing of AEs result ing in dose reductio n of any study  drug will be presented.  
All AEs result ing in dose reduction of any study  drug occurring on -study  will be displayed.

MLN9708
Statistical Analysis Plan Study C16020
345.11.1.7    Dose Limiting Toxicities (DLTs)
A by-patient listing of DLTs that occur during Cycle 1 of treatment will be presented only 
forpatients participating in the safety lead-in.
5.11.2    Laboratory Data
For the purposes of summarizat ion in both the tables and list ings, all laboratory values will 
be converted to standardized units.  If a lab value is reported using a non -numeric qualifier 
(e.g., less than (<) a certain value, or greater than (>) a certain value), the given numeric 
value will be used in the summary statist ics, ignoring the non -numeric qualifier. However, 
for the bone m arrow pl asma cell percentage, the convent ion of (x -1)% (m ainly for < 5% for 
CR) will be used.
Laboratory  test resul ts from the central  laboratory  will be used when they  are available.  
Laboratory  test resul ts from local laborator ieswill be used only when no central laboratory  
test results exist at the same sampl e collecti on time point , unless specified otherwise .
Laboratory  test resul ts will be summarized according to the scheduled sample co llection 
time point.  Change fro m baseline will also be presented. The parameters to be analyzed 
include ,but are not limite d to:
Hem atology:  hem oglobin, hematocri t, platelet count, leukocytes with
different ial,andneutrophils (abso lute neutrophil count [ANC])
Clinical chemistr y:  blood urea nitrogen, creatinine, total bilirubin, urate, lactate
dehydrogenase (LDH), gamma glutamyl  transferase (GGT), phosphate , albumin,
alkaline phosphatase ( ALP ), aspartate aminotransferase ( AST ), alanine
aminotransferase ( ALT ), glucose, calci um, sodi um, potassi um, chloride, carbon
dioxide (CO 2),and magnesium.
Shift tables the change in CTCAE grade will be constructed for hematology and chemistry  
laboratory  parameters which have corresponding CTCAE grades to tabulate changes in NCI 
CTCAE (versio n 4.03)(1)from baseline to worst post baseline on study  CTC AEgrade.  All 
the data fro m both scheduled and unscheduled time points are to be included in the shift 
table. However, at each time point, the central lab value is used preferent ially. Only  when 
the central  lab value is not available will the local lab value be used
Worst changes from baseline for creatinine clearance will be tabulated and categori zed by ≤ 
30 mL/min and > 30 mL/min , and 
≤ 60 mL/min and > 60 mL/min.

MLN9708
Statistical Analysis Plan Study C16020
35The m ean and median est imates over time may be graphed for a selected list of lab
param eters. These include but not limited to: LDH, creatinine, albumin, calcium, sodium, 
and phosphate from serum chemistry  and WBC, absol ute neutrophil  count, hem oglobin, 
platelet count from hematol ogy. 
For pati ents wi th NDMM who enter m aintenance therapy after 13 cy cles of inducti on 
treatm ent, sel ected hematol ogical parameters such as ANC, ALC, platelets, hemoglobin may 
be analyzed by  induct ion phase and maintenance phase separately .
The box plots of cre atinine, M -protein values, change of M -protein from  baseline over time 
will be graphed as well.  For mean/median figures over time and box plots over time, only the 
data from  scheduled t ime points are included. At the same scheduled time po int, if the cent ral 
lab value is available, then it is used. Only if the central lab value is not available will the 
local lab value be used.
If appropriate, line graphs of individual tests over time will be used to show changes in 
laboratory  measures over time for each individual patient. For figures showing the individual -
patient lab values over time, all scheduled and unscheduled t ime points are included. At the 
same time point, if the central lab value is available, it is used; if not, the local lab value is 
used.
By-patient listings to be presented include hematology ,clinical chemistry and urinalysis .
5.11.3    Vital Signs
The actual  values of vital sign parameters including oral temperature, pulse rate, sy stolic and 
diastolic blood pressure, and weight, w ill be summari zed over time for each treatment arm 
and the total of Arm A + Arm B . Change fro m baseline will also be presented. A by -patient 
listing will also be presented.
5.11.4    Electrocardiograms
ECGs, including abnormalit ies,will be listed in a by -patient listing.
QTc interval will be calculated using Bazett’s correction and Fridericia’s correction.  The 
formulas are:
QTc (Bazett) = QT / (RR0.5)
QTc (Fridericia) = QT / (RR0.33)

MLN9708
Statistical Analysis Plan Study C16020
36where RR = 60 / heart rate (bpm)
5.11.5    Eastern Cooperative Oncology Group Performance Statu s
Eastern Cooperative Oncology  Group perform ance status over time will be summarized.  
Shift s from baseline to postbaseline over time will be summarized by treatm ent arm and the 
total of Arm A + Arm  B.  
5.11.6    Other Safety Assessments
Pregnancy testing results will be presented in a by -patient list ing.
Addit ional safet y analyses m ay be determined at any  time to enumerate rates of toxicit ies 
and to further define the safet y profile o f the study  drugs. 
6.   CHANGES TO PLANNED A NALYSES FROM PROTOCOL
There are no change sto the planned analyses from that described in the protocol .
Reference materials for this statist ical plan include Clinical Study Protocol C16020 
Amendment 1 (May 2014). 
7.   PROGRAMMING CONSIDER ATIONS
7.1   Statistical Sof tware 
SAS versio n 9.2(or hi gher) will be used for all analyses .  
7.2   Rules and Definitions
Patientpopulat ions are defined in Section 2.
Baseline values are defined in Sect ion 5.4.2 .
8.   REFERENCES
1.Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. 
Internation al uniform response cri teria for m ultiple myelo ma. Leukemia 2006; 20(9): 
1467-
73.
2.Mosteller RD: Simplified Calculat ion of Body  Surface Area. N Engl J Med 1987 Oct 
22;317(17):1098 (letter).
3.U.S. Department of Health and Human Services, National Inst itutes of Health 
National Cancer Inst itute. Commo n Termino logy Cri teria for Adverse Events 
(CTCAE). Version 4.03. 14 June 2010.

MLN9708
Statistical Analysis Plan Study C16020
374.Lee JJ, Liu DD. A predict ive probabilit y design for phase II cancer clinical trials.
Clin Tri als 2008;5(2):93 -106.
5.Thall PF, Sung HG: So me extensions and applicat ions of a Bayesian strategy  for
monitoring mul tiple outcom es in clinical trials. Statist ics in Medicine 1998; 17(14):
1563-80.
